Search
Close this search box.

Øystein Fluge, MD, PhD

Dr. Fluge has been courageous in pursuing his observations on the effects of rituximab on ME / CFS patients when that issue was not the planned focus of his investigation. He has now completed a double-blind, well-controlled, multi-center clinical trial on the effects of Rituxamab, and will discuss those results upon receiving notice of acceptance of his publication. He has continued to follow where the data lead him into cellular and molecular analyses. This kind of excellent, open-minded science is just what we need in our quest for an end to ME / CFS.
Dr. Fluge is the Senior Consultant supervising the ME / CFS research group at the Department of Oncology and Medical Physics at the University of Bergen, Haukeland University Hospital, Bergen, Norway. Drs. Fluge and Mella work together on the Norwegian Rituximab and cyclophosphamide trials with ME / CFS patients.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.


How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669